Healthcare Providers Must Combine Zero Trust Architecture and Threat Modeling to Address Cybersecurity Challenges

healthspry banner ad

 

In today’s increasingly digital world, the healthcare sector faces significant cybersecurity challenges, necessitating urgent and sophisticated responses. The recent draft guidance issued by the FDA on cybersecurity for medical devices highlights a critical juncture for the industry: the need to implement and scale best practices in cybersecurity is more pressing than ever. As healthcare continues to integrate advanced technology, from medtech devices to comprehensive electronic health records, the potential for security breaches grows, underscoring the stakes involved in protecting sensitive health information.

What are the most effective strategies for healthcare organizations to not only implement but also scale and automate these cybersecurity best practices?

Mike Isbitski, the Director of Cybersecurity Strategy at Sysdig shares his take on the imperative role of implementing and scaling cybersecurity best practices in the healthcare industry on an episode of Expert’s Talk. Isbitski emphasizes the importance of adopting a zero-trust architecture, threat modeling and enhancing supply chain security through comprehensive management of software and hardware components and more to tackle cybersecurity challenges in healthcare.

Here are the key takeaways from Isbitski’s analysis:

  • Zero Trust Architecture: Emphasizing the shift towards a zero trust framework, which is crucial for protecting against internal and external breaches.
  • Supply Chain Risks: Highlighting the importance of understanding and securing the supply chain, particularly with the use of Software and Hardware Bills of Materials (SBOMs and HBOMs) to manage risks effectively.
  • Regulatory Guidance: Discussing the new FDA cybersecurity guidelines, which aim to tailor cybersecurity measures specifically for the healthcare and medtech sectors.
  • Automation and Scalability: Addressing the critical need for cybersecurity strategies to be scalable and automated to handle the increasing volume and sophistication of threats.
  • Threat Modeling: Advocating for a proactive approach in threat modeling to anticipate and mitigate potential security threats before they materialize.

Article written by Sonia Gossai

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More